Gilead Sciences is facing criticism for the price of its hepatitis C drug, Sovaldi, in the US, but has tried to sidestep the problem in developing countries with a series of licensing deals. In India, Gilead has signed agreements with manufactures to sell low-cost Sovaldi and a follow-up combo with ledipasvir, in return for a license fee and 7% royalties on sales, to 91 countries around the world. Many critics would like to see this coverage expanded to include Mexico, more countries in South America, Central America and the Caribbean, greater coverage of South and Central Asia, North Africa and Eastern Europe. Read more here. (Source: PMGroup, 2014).
You are here: / / Gilead Faces Criticism With Sovaldi’s Humanitarian Program